Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis...

Full description

Bibliographic Details
Main Authors:	Afshin Amini, Samar Masoumi Moghaddam, David L. Morris, Mohammad H. Pourgholami
Format:	Article
Language:	English
Published:	Hindawi Limited 2012-01-01
Series:	Journal of Oncology
Online Access:	http://dx.doi.org/10.1155/2012/540791

id	doaj-7e122ad92611405b9c221052ab9382c5
record_format	Article
spelling	doaj-7e122ad92611405b9c221052ab9382c52020-11-24T22:26:34ZengHindawi LimitedJournal of Oncology1687-84501687-84692012-01-01201210.1155/2012/540791540791Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to ApplicationAfshin Amini0Samar Masoumi Moghaddam1David L. Morris2Mohammad H. Pourgholami3Cancer Research Laboratories, Department of Surgery, St George Hospital (SESIAHS), The University of New South Wales, Sydney, NSW 2217, AustraliaCancer Research Laboratories, Department of Surgery, St George Hospital (SESIAHS), The University of New South Wales, Sydney, NSW 2217, AustraliaDepartment of Surgery, St George Hospital (SESIAHS), The University of New South Wales, Sydney, NSW 2217, AustraliaCancer Research Laboratories, Department of Surgery, St George Hospital (SESIAHS), The University of New South Wales, Sydney, NSW 2217, AustraliaDespite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies.http://dx.doi.org/10.1155/2012/540791
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Afshin Amini Samar Masoumi Moghaddam David L. Morris Mohammad H. Pourgholami
spellingShingle	Afshin Amini Samar Masoumi Moghaddam David L. Morris Mohammad H. Pourgholami Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application Journal of Oncology
author_facet	Afshin Amini Samar Masoumi Moghaddam David L. Morris Mohammad H. Pourgholami
author_sort	Afshin Amini
title	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_short	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_full	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_fullStr	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_full_unstemmed	Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application
title_sort	utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application
publisher	Hindawi Limited
series	Journal of Oncology
issn	1687-8450 1687-8469
publishDate	2012-01-01
description	Despite recent advances in the management of ovarian cancer, it remains the most lethal gynecologic malignancy. Vascular endothelial growth factor (VEGF) has been shown to play a pivotal role in the progression of ovarian cancer leading to the eventual development of malignant ascites. On this basis, agents rendering VEGF ineffective by neutralizing VEGF (bevacizumab), blocking its receptors (aflibercept), or interfering with the postreceptor signaling pathways (sunitinib) provide us with the rational treatment options. These agents are generally used in combination with the standard chemotherapeutic drugs. Here, we discuss the basis of and the logic behind the use of these agents in the treatment of epithelial ovarian cancer, as well as their evaluation in different preclinical and clinical studies.
url	http://dx.doi.org/10.1155/2012/540791
work_keys_str_mv	AT afshinamini utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT samarmasoumimoghaddam utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT davidlmorris utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication AT mohammadhpourgholami utilityofvascularendothelialgrowthfactorinhibitorsinthetreatmentofovariancancerfromconcepttoapplication
_version_	1725752936570552320

Utility of Vascular Endothelial Growth Factor Inhibitors in the Treatment of Ovarian Cancer: From Concept to Application

Similar Items